Evidence map›Paper›PMID 36839377›Full record

ArticleNutrients2023

Agarwood Oil Nanoemulsion Attenuates Cigarette Smoke-Induced Inflammation and Oxidative Stress Markers in BCi-NS1.1 Airway Epithelial Cells.

Gabriele De Rubis, Keshav Raj Paudel, Bikash Manandhar, Sachin Kumar Singh, Gaurav Gupta, Raniya Malik, Jessie Shen, Aniss Chami, Ronan MacLoughlin, Dinesh Kumar Chellappan and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Protective Effect ofNutrients · 2023
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Gabriele De RubisDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0001-7088-396X
Keshav Raj PaudelCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.ORCID 0000-0002-3591-2080
Bikash ManandharDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0003-1276-6954
Sachin Kumar SinghFaculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0003-3823-6572
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India.
Raniya MalikDeÁurora Pty Ltd., Dean, VIC 3363, Australia.
Jessie ShenDeÁurora Pty Ltd., Dean, VIC 3363, Australia.
Aniss ChamiVitex Pharmaceuticals, Eastern Creek, NSW 2766, Australia.
Ronan MacLoughlinAerogen, IDA Business Park, H91 HE94 Galway, Ireland.ORCID 0000-0002-3164-1607
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.ORCID 0000-0001-5567-6663
Brian Gregory George OliverWoolcock Institute of Medical Research, University of Sydney, Sydney, NSW 2037, Australia.ORCID 0000-0002-7122-9262
Philip Michael HansbroCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.ORCID 0000-0002-4741-3035
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-7507-1159
University of Technology Sydney · AUIMU University · MYLovely Professional University · INRoyal College of Surgeons in Ireland · IEUttaranchal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is an irreversible inflammatory respiratory disease characterized by frequent exacerbations and symptoms such as cough and wheezing that lead to irreversible airway damage and hyperresponsiveness. The primary risk factor for COPD is chronic cigarette smoke exposure, which promotes oxidative stress and a general pro-inflammatory condition by stimulating pro-oxidant and pro-inflammatory pathways and, simultaneously, inactivating anti-inflammatory and antioxidant detoxification pathways. These events cause progressive damage resulting in impaired cell function and disease progression. Treatments available for COPD are generally aimed at reducing the symptoms of exacerbation. Failure to regulate oxidative stress and inflammation results in lung damage. In the quest for innovative treatment strategies, phytochemicals, and complex plant extracts such as agarwood essential oil are promising sources of molecules with antioxidant and anti-inflammatory activity. However, their clinical use is limited by issues such as low solubility and poor pharmacokinetic properties. These can be overcome by encapsulating the therapeutic molecules using advanced drug delivery systems such as polymeric nanosystems and nanoemulsions. In this study, agarwood oil nanoemulsion (agarwood-NE) was formulated and tested for its antioxidant and anti-inflammatory potential in cigarette smoke extract (CSE)-treated BCi-NS1.1 airway basal epithelial cells. The findings suggest successful counteractivity of agarwood-NE against CSE-mediated pro-inflammatory effects by reducing the expression of the pro-inflammatory cytokines IL-1α, IL-1β, IL-8, and GDF-15. In addition, agarwood-NE induced the expression of the anti-inflammatory mediators IL-10, IL-18BP, TFF3, GH, VDBP, relaxin-2, IFN-γ, and PDGF. Furthermore, agarwood-NE also induced the expression of antioxidant genes such as GCLC and GSTP1, simultaneously activating the PI3K pro-survival signalling pathway. This study provides proof of the dual anti-inflammatory and antioxidant activity of agarwood-NE, highlighting its enormous potential for COPD treatment.

Indexed as

Cigarette SmokingPulmonary Disease, Chronic ObstructiveAnti-Inflammatory AgentsAntioxidantsEpithelial CellsInflammationNicotianaOxidative StressAnti-Inflammatory AgentsAntioxidantsagarwoodchronic obstructive pulmonary diseasecigarette smokedrug deliveryinflammationnanoemulsionnutraceuticalsphytoceuticals

Identifiers

PMID36839377
PMCPMC9959783
OpenAlexW4321375883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.